Malignant hypertension.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000097:blood; D000818:Animals; D001161:Arteriosclerosis / Q000150:complications; D003981:Diazoxide / Q000627:therapeutic use; D004285:Dogs; D006439:Hemodynamics; D006801:Humans; D006974:Hypertension, Malignant / Q000097:blood / Q000209:etiology / Q000628:therapy; D006977:Hypertension, Renal / Q000097:blood / Q000209:etiology / Q000628:therapy*; D009392:Nephrectomy; D051381:Rats; D006435:Renal Dialysis; D012083:Renin / Q000097:blood; D013562:Sympathectomy; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D014665:Vasodilator Agents; D000804:Angiotensin II; D000450:Aldosterone; D012083:Renin; D003981:Diazoxide